At the same time, targeting regulatory factors such as VEGFA, which play a key role in both solid tumors and hematological tumors, is expected to further expand the clinical application scenarios of CAR T-cell therapy and enhance its efficacy. The gene discussed is VEGFA; the disease is hematopoietic and lymphoid cell neoplasm.